¼¼ÊõÎÄÕÂ
Technical articlesSpotTM ˫ĿÊÓÁ¦É¸²éÒÇÔÚ¼ì²éÖйúÑۿƾÍÕïµÄѧÁäǰ ¼°Ñ§Áä¶ùͯÈõÊÓΣÏÕÒòËØµÄÓ¦ÓÃ
ÄÂÑǾý£¬¶¡¸Õ£¬Îºéª£¬»ªÄþ£¬Ç®Ñ§º²£¬Ìì½òÒ½¿Æ´óѧÑÛ¿ÆÒ½ÔºÐ±ÊÓÓëС¶ùÑÛ¿Æ ÀîóãÈÙ£¬Ìì½òÒ½¿Æ´óѧÑÛ¿ÆÒ½Ôº²£Á§ÌåÊÓÍøÄ¤ÓëÑÛÍâÉË¿Æ
Hua Bi£¬Edgar Ekure£¬ÃÀ¹úŵÍß¶«ÄÏ´óѧÊÓ¹âѧԺ
¡¾ÕªÒª¡¿
Ä¿µÄ£º±¾Ñо¿µÄÄ¿µÄÊÇΪÁËÆÀ¹À Spot ˫ĿÊÓÁ¦É¸²éÒÇÔÚ¼ì²é·ûºÏ 2013 ÄêÃÀ¹úбÊÓÓëС¶ùÑÛ¿ÆÐ»á
£¨AAPOS£©±ê×¼µÄÖйúѧÁäǰºÍѧÁä¶ùͯÖеÄÈõÊÓΣÏÕÒòËØµÄÓÐЧÐÔ¡£
·½·¨£ºÄêÁäÔÚ 4 ÖÁ 7 ËêÖ®¼ä£¨5.74±1.2 Ë꣩µÄ 155 Ãû¶ùͯ£¨310 Ö»ÑÛ£©£¬½øÐÐÁËÍêÕûµÄÑۿƼì²é¡¢ ÊÓÁ¦É¸²éºÍɢͫ¼ìÓ°Ñé¹â¡£ÀûÓÃÏßÐԻعéºÍ Bland-Altman ͼÀ´ÆÀ¹ÀÊÓÁ¦É¸²éºÍɢͫ¼ìÓ°Ñé¹âËù»ñµÃ µÄ¼ì²é½á¹ûµÄÒ»ÖÂÐÔ¡£¸ù¾Ý AAPOS 2013 ×¼ÔòÀ´¼ÆËãÈõÊÓΣÏÕÒòËØ¼ì²éµÄÃô¸Ð¶ÈºÍÌØÒì¶È¡£Ê¹ÓÃÊÜÊÔ Õß²Ù×÷ÌØÕ÷£¨ROC£©ÇúÏßÀ´·ÖÎö¼ì²éÈõÊÓΣÏÕÒòËØµÄ×ÜÌåÓÐЧÐÔ¡£
½á¹û£ºÊ¹Óà Spot ¼ì²éµÄƽ¾ùÇü¹â²»ÕýΪ£ºµÈЧÇò¾µ¶È£¨SE£©= 0.70±1.99 D£¬J0 = 0.87±1.01 D£¬ J45 = 0.09±0.60 D¡£É¢Í«¼ìÓ°Ñé¹â¼ì²éµÄƽ¾ù½á¹ûΪ£ºSE = 1.19±2.22 D£¬J0 = 0.77±1.00
D£¬J45 = -0.02±0.45 D¡£ÕâÁ½ÖÖ·½·¨»ñµÃµÄ½á¹ûÖ®¼ä´æÔÚÇ¿ÁÒµÄÏßÐÔÒ»ÖÂÐÔ£¨R2 = 0.88£¬P
<0.01£©¡£Bland-Altman ͼ±íÏÔʾÕâÁ½ÖÖ·½·¨¼ì²éÖù¾µµÄ½á¹ûÖ®¼ä´æÔÚÖеȵÄÒ»ÖÂÐÔ¡£¸ù¾Ý AAPOS
2013 Ö¸ÄϹ涨µÄ±ê×¼£¬¼ì²éÔ¶ÊÓµÄÃô¸Ð¶ÈºÍÌØÒì¶È£¨ÒÀ´Î£©·Ö±ðΪ 98.31£¥ºÍ 97.14£¥£»¼ì²é½ü ÊÓµÄÃô¸Ð¶ÈºÍÌØÒì¶È·Ö±ðΪ 78.50£¥ºÍ 88.64£¥£»¼ì²éÉ¢¹âµÄÃô¸Ð¶ÈºÍÌØÒì¶È·Ö±ðΪ 90.91£¥ºÍ
80.37£¥£»¼ì²éÇü¹â²Î²îµÄÃô¸Ð¶ÈºÍÌØÒì¶È·Ö±ðΪ 93.10£¥ºÍ 85.25£¥£»¶ø¼ì²éбÊÓµÄÃô¸Ð¶ÈºÍÌØÒì ¶È·Ö±ðΪ 77.55£¥ºÍ 88.18£¥¡£
½áÂÛ£ºSpot ˫ĿÊÓÁ¦É¸²éÒDzâÁ¿µÄÕÛÉäÖµÓëɢͫ¼ìÓ°Ñé¹âµÄ½á¹ûÏÔʾ³öÖеȵÄÒ»ÖÂÐÔ£¬È»¶ø×ÜÌåµÄ ½üÊÓÒÆÎ»Îª -0.49D¡£¼ì²é¸öÌåÈõÊÓΣÏÕÒòËØµÄ±íÏÖÁîÈËÂúÒ⣬µ«¿ÉÒÔͨ¹ý»ùÓÚ ROC ÇúÏßµÄÓÅ»¯±ê×¼ ½øÒ»²½¸Ä½ø¡£
¡¾½éÉÜ¡¿
ÔÚ¹¤Òµ»¯¹ú¼ÒÖУ¬ÈõÊÓÊǶùͯ¿ÉÔ¤·ÀÊÓÁ¦ÕϰµÄ*³£¼ûÔÒò£¬·¢²¡ÂÊΪ 1.6% ¡« 3.6%1¡£Èç¹û²»¼°Ê±ÖÎÁÆ£¬ ÈõÊÓͨ³£»áµ¼ÖÂÉú»îÖÊÁ¿Ï½µºÍÊÓÁ¦¹¦ÄܵÄË«²àÕϰ 2¡£ÈõÊÓµÄΣÏÕÒòËØ°üÀ¨Ð±ÊÓ¡¢Çü¹â²»ÕýºÍ¹âÉ¥ ʧ 3¡£Í¨¹ý·ÇÈõÊÓÑ۵Ĵ¦·½ÑÛ¾µºÍ / »ò±ÕÈûÖÎÁÆ£¬¿ÉÒÔÔڹؼüµÄ·¢ÓýÆÚÄڳɹ¦µÄÖÎÁÆÈõÊÓ 1¡£ÃÀ¹úÔ¤ ·À·þÎñ¹¤×÷×飨USPSTF£©ÉùÃ÷Ö¸³ö£¬3 ÖÁ 5 Ëê¶ùͯµÄÈõÊÓ¼ì²éºÍÖÎÁÆ¿ÉÒÔ´ó´óµÄ¸ÄÉÆÊÓÁ¦ 4¡£È»¶ø£¬ ûÓÐ×ã¹»µÄÖ¤¾ÝÀ´ÆÀ¹À 3 ËêÒÔ϶ùͯÊÓÁ¦É¸²éµÄºÃ´¦ºÍ / »òΣº¦ 4¡£ÃÀ¹ú¶ùͯÑÛ²¡Ñо¿Ð¡×é (Pediatric Eye Disease Investigator Group) ÈÏΪ£¬ÖÎÁÆÈõÊÓµÄ*¼Ñʱ¼äÊǶùͯÄêÁäСÓÚ 7 Ëêʱ 5¡£ÓÉÓÚÈõÊÓ ÔÚÔçÆÚ½×¶ÎÊÇ¿ÉÒÔÔ¤·ÀºÍÖÎÁƵģ¬Òò´ËÃÀ¹ú¶ùͯÑۿƺÍбÊÓлᣨAAPOS£©¡¢ÃÀ¹ú¶ù¿ÆÑ§»á£¨AAP£©¡¢ ÃÀ¹úÔ¤·À·þÎñ¹¤×÷×飨USPSTF£©¶ÔÓÚÊÓÁ¦É¸²é¹ã·ºÍƼö 4¡¢6¡£ÓÐÁ½ÏîÀúÊ·±È½ÏÑо¿Ö¸³ö£¬Ó¦ÓÃÊÓÁ¦É¸ ²é¿ÉÒÔ¼õÉÙÈõÊӵϼ²¡ÂÊ 7¡¢8¡£
»ùÓÚÒÇÆ÷µÄÊÓÁ¦É¸²éÊÇÒ»¸ö¼¸ºõ²»ÐèÒª¶ùͯºÏ×÷µÄ¿ìËÙ¹ý³Ì£¬±»ÊÓΪÊÓÁ¦É¸²éµÄ·½°¸£¬ÌرðÊÇ ¶ÔÓÚ·¢Óý³Ù»ºµÄºÍÇ°ÃæÌáµ½µÄ¶ùͯ 4¡¢9¡£Spot ÊÇÒ»¿îпª·¢µÄ±ãЯµÄÊÖ³ÖʽºìÍâÊÓÁ¦É¸²éÒÇ£¨Welch Allyn£¬Skaneateles Falls£¬NY£©¡£ÔÚɸ²é¹ý³ÌÖУ¬¼ì²éÕß»áÒªÇóÊÜÊÔÕß˫Ŀ¹Û¿´ÒÇÆ÷¡£ÀûÓóɹ¦ »ñµÃµÄºìÉ«·´Éä³ÉÏñ£¬É豸½«»áÁ¢¼´×Ô¶¯¼ÆËã·ÇɢͫÇü¹â״̬¡¢Í«¿×´óС¡¢Í«¿×¼ä¾àºÍÄýÊÓÆ«ÊÓ¡£ Èç¹û¼ì²éµ½Ã÷ÏÔµÄÇü¹â²»Õý¡¢Çü¹â²Î²î¡¢Í«¿×²»µÈ´ó»òÕßбÊÓ£¬ÒÇÆ÷½«»á±ê¼ÇΪתÕïµ½*µÄÑÛ¾¦ ¼ì²é 10¡¢11¡£Spot ˫ĿÊÓÁ¦É¸²éÒÇÏÔʾ³ö´ó¹æÄ£É¸Ñ¡µÄ¾Þ´óǰ¾°£¬ÓÐÒÔϼ¸¸öÔÒò¡£Ê×ÏÈ¡¢¸Ã¼ì²é¿É ÒÔ¾àÀ뺢×ÓÃÇ´óÔ¼Ò»Ãס£Õâ¸ö¹¤×÷¾àÀë¿ÉÒÔÈú¢×ÓÃÇ·ÅËÉ£¬²¢ÇÒ¿ÉÒÔ·½±ãÄÇЩ²Ð¼²ÈË£¬±ÈÈç¼¹Ëè»Ò ÖÊÑ×»¼ÕߺÍ×Ô±ÕÖ¢»¼Õß¡£µÚ¶þ¡¢ÓÉÓÚÁ½Ö»ÑÛ¾¦¿ÉÒÔͬʱ½ÓÊܼì²é£¬ËùÒÔÊý¾Ý²É¼¯Ê±¼äºÜ¶Ì£¬´óÔ¼ÔÚ 2 ÃëÄÚ 11¡£¿¼Âǵ½ÖйúÈË¿ÚÖÚ¶àµÄÇé¿ö£¬ÕâÏîÓÅÊÆ¸ü¼ÓÖØÒª¡£µÚÈý¡¢ËüÊÇ×Ô¶¯»¯µÄ£¬¿ÉÒÔÓÉûÓоÑéµÄ ɸ²éԱʹÓá£Õâ¶ÔרҵÑÛ¿ÆÒ½Éúȱ·¦µÄÖйúÓÈÎªÖØÒª¡£µÚËÄ¡¢¸ÃÉ豸ÊÇµç³Ø¹©µçºÍ±ãЯʽµÄ£¬Òò´Ë ¿ÉÒÔÓÃÓÚ¸÷ÖÖɸѡ»·¾³ 10¡£
*½üÓÐһЩÎÄÕ£¬±¨µÀÁË Spot ɸ²éÈõÊÓΣÏÕÒòËØµÄÃô¸Ð¶ÈºÍÌØÒì¶È 10-12¡£ËäÈ»ÕâЩÑо¿±¨¸æÁË»ùÓÚ AAPOS Ö¸ÄÏ ] »òÕßÖÆÔìÉ̶¨ÒåµÄ±ê×¼À´¼ì²éÈõÊÓΣÏÕÒòËØ£¬¾ßÓÐÏ൱¸ßµÄÃô¸Ð¶ÈºÍÌØÒì¶È£¨Ãô¸Ð¶È ·¶Î§´Ó 87£¥ÖÁ 89£¥£¬ÌØÒì¶È·¶Î§Îª 71£¥ÖÁ 75.9£¥£©£¬È»¶ø£¬Éв»ÖªµÀ¸Ã±ê×¼ÊÇ·ñ¿ÉÒÔÓÅ»¯ÒÔ´ïµ½ Æä*¼ÑÐÔÄÜ¡£´ËÍ⣬ËùÓеÄÕâЩÑо¿¶¼ÊÇÔڸ߼ÓË÷ÈË¿ÚÖнøÐеġ£¶ÔÓÚÖйúÈËȺ¶øÑÔ£¬ÈõÊÓ»¼²¡ÂÊ ½Ï¸ß£¬Ö÷ÒªÊÇÇü¹â²»ÕýºÍбÊÓÒýÆðµÄ£¬Spot ¼ì²éÖйúÈËȺÈõÊÓΣÏÕÒòËØµÄ׼ȷÐÔÉв»È·¶¨ 14 ¡£Òò´Ë£¬ ±¾Ñо¿µÄÄ¿µÄÊÇÆÀ¹À Spot ÔÚÖйúѧÁäǰºÍѧÁä¶ùͯÖÐʹÓà AAPOS 2013 ×¼Ôò¼ì²éÈõÊÓΣÏÕÒòËØµÄÓРЧÐÔ£¬²¢ÇÒͨ¹ý°´ÕÕ ROC ·ÖÎöÀ´ÓÅ»¯¼ì²éÈõÊÓΣÏÕÒòËØµÄÖ¸ÄÏÀ´È·¶¨ÈçºÎ¸Ä½ø¡£
¡¾·½·¨¡¿
Ìì½òÒ½¿Æ´óѧÑÛ¿ÆÒ½ÔºÂ×ÀíίԱ»áÅú×¼±¾Ñо¿£¬²¢ÇÒÔÚÑо¿¿ªÊ¼ÒÔǰ»ñµÃ¼Ò³¤µÄÖªÇéͬÒâÊé¡£ËùÓÐ ÎÊÌâºÍÒÉÂǶ¼ÔÚÇ©ÊðÖªÇéͬÒâÊé֮ǰµÃµ½½â¾ö¡£Ñо¿µÄ½øÐÐ×ñÑÁ˺նûÐÁ»ùÊ®¶þÔµÄ×ÚÖ¼¡£¿¼Âǵ½ ÏÈÌìÐÔ°×ÄÚÕÏ»òÉÏíúÏ´¹µÈ¹âɥʧµÄ·¢ÉúÂʵͣ¬ÎÒÃǵÄÑо¿ÖÐÅųýÁËÕâЩ¼²²¡¡£À´ÑÛ¿ÆÒ½Ôº½øÐÐɸ ²é»òÕß×ö¼ì²éµÄÄêÁäÔÚ 4 µ½ 7 ËêÖ®¼äµÄ¶ùͯ±»ÄÉÈëµ½±¾ÏîÑо¿ÖС£
ËùÓеϼÕß¶¼°´ÕÕÒÔÏÂ˳Ðò½øÐмì²é£º£¨1£©ÍêÕûÑۿƼì²é£»£¨2£©Spot ˫ĿÊÓÁ¦É¸²éÒǼì²â£»£¨3£©É¢Í«£»£¨4£© ÊÓÍøÄ¤¼ì²é¡£ÔÚÊÓÁ¦É¸²é¹ý³ÌÖУ¬SpotÔÚ¾àÀë¶ùͯһÃ×µÄλÖýøÐмì²é¡£SpotµÄ²âÁ¿·¶Î§Îª+/-7.50 D¡£ Èç¹ûÇü¹â¶È³¬³ö·¶Î§£¬ÄÇô´¥ÃþÆÁÉϽ«»áÏÔʾ >7.50 »ò <-7.5015¡£²âÊÔÓÉ·ÇרҵµÄѵÁ·ÓÐËØµÄ¹¤×÷ÈË Ô±½øÐУ¬ËûÃÇͨ¹ýÿ¸öº¢×Ó 3 ´Î»òÕ߸üÉٵļì²é»ñµÃÿ¸öº¢×ӵĽá¹û¡£Ã¿Ö»ÑÛ¾¦Ã¿ 5 ·ÖÖӵμӸ´·½ ÍÐßÁ¿¨°·µÎÑÛÒºÒ»´Î£¬¹²¼Æ 20 ·ÖÖÓ£¬²¢ÔÚ*ÖÕµÎ×¢ºó 20 ÖÁ 25 ·ÖÖÓ½øÐÐÊÓÍøÄ¤¼ì²é¡£ÊÓÍøÄ¤¼ì²éÓÉ ×¨ÒµÑé¹âʦÀ´Íê³É¡£¼Ç¼ÿһֻÑÛ¾¦µÄ*¼Ñ½ÃÕýÊÓÁ¦£¨BCVA£©¡£Ñé¹âʦ²¢²»ÖªµÀ Spot ˫ĿÊÓÁ¦É¸²é ÒǵĽá¹û£¬ÒÔ±ÜÃâDZÔ򵀮«ÒС£ÓÉÑÛ¿ÆÒ½ÉúʹÓÃÕÚ¸Ç - È¥ÕÚ¸Ç (cover-uncover test) ·½·¨¼ì²éбÊÓ¡£ Èç¹û·¢ÏÖÓÐÃ÷ÏÔбÊÓ£¬¾ÍҪͨ¹ýÀâ¾µ·¨²â¶¨Æ«²îÁ¿¡£
ÿֻÑÛ¾¦Ê¹ÓÃɢͫÑé¹â·½·¨²âÁ¿ 5 ´ÎÇü¹â²»Õý£¬°üÀ¨£º£¨Çò¾µ [S]£¬Öù¾µ [C]£¬ÖùÖá [a]£©£¬²¢ÇÒ¼Æ ËãÆ½¾ùʸÁ¿Öµ×÷Ϊ*ÖÕ½á¹û¡£¸ù¾ÝÒÔϹ«Ê½¼ÆËãÇò¾µÇü¹â£¨SE£©ÒÔ¼° J0 ºÍ J45 µÄÉ¢¹âʸÁ¿±íÏÖ£ºSE
= S+C/2£»J0 =£¨-C/2£©*cos£¨2*ϑ£©£»J45=£¨-C/2£©*sin£¨2*ϑ £©¡£¼ÆËãÒì³£Çü¹â¶ÈΪ SE ÖеÄÑÛ¼ä
²îÒì¡£
ÈõÊÓµÄΣÏÕÒòËØÊǸù¾Ý AAPOS 2013 Ö¸ÄÏÖÐÄêÁ䳬¹ý 48 ¸öÔµģºÈκÎ×ÓÎçÏßÖеÄÔ¶ÊÓ > 3.5 D£¬ÈκΠ×ÓÎçÏßÖеĽüÊÓ > -1.5 D£¬ÈκÎ×ÓÎçÏßÖеÄÉ¢¹â > 1.5 D£»Çü¹â²Î²î > 1.5D£¬Ô·¢²¿Î»µÄÃ÷ÏÔбÊÓ
> 8PD13¡£Spot ¼ì²éºÍɢͫ¼ìÓ°Ñé¹â¶¼ÊÇ»ùÓÚÕâЩ±ê×¼½øÐзÖÎö¡£ÈõÊÓÊǸù¾Ýʵ¼ùģʽ£¨PPP£©¶¨ ÒåµÄ 2£ºµ¥²àÈõÊÓ > = 2 ÏßÑÛ¼ä²îÒ죻˫ÑÛÈõÊÓ£ºÄêÁä > = 4 Ë꣺ÈκÎÒ»ÑÛµÄÊÓÁ¦²îÓÚ 20/40 µÄ¡£
ÃèÊöÐÔͳ¼Æ°üÀ¨Æ½¾ùÊý¡¢±ê×¼²îºÍƵÊýµÄ²âÁ¿¡£ÓÉÓÚ Kolmogorov-Smirnov ¼ìÑé±íÃ÷£¬¸ÃÊý¾Ý²¢·ÇÕý ̬·Ö²¼£¬Òò´ËÓ¦Óà Wilcoxon ÖȺͼìÑéÀ´²âÊÔ Spot ºÍɢͫ¼ìÓ°Ñé¹â¼ì²éµÄ½á¹ûÖ®¼äµÄ²îÒìÊÇ·ñÏÔÖø¡£ ½¨Á¢ÏßÐÔ¡¢¶þ´Î·½¡¢Èý´Î·½ÌåÄ£ÐÍÀ´ÆÀ¹ÀÕâÁ½ÖÖ·½·¨»ñµÃµÄ¼ì²é½á¹ûÖ®¼äµÄÏà¹ØÐÔ¡£ÀûÓà Bland- Altman ͼÀ´ÆÀ¹À Spot ºÍɢͫ¼ìÓ°Ñé¹â¼ì²éÖ®¼äµÄÒ»ÖÂÐÔ¡£²ÉÓÃÊÜÊÔÕßÊÖÊõÌØÕ÷£¨ROC£©ÇúÏßÀ´Ñ¡Ôñ ÓÐ¹Ø Spot ¼ì²éµÄÊʵ±Ãô¸Ð¶ÈºÍÌØÒì¶ÈÐÔµÄ*¼Ñ½ØÖ¹µã£¬ÒÔ¼ì²éÈõÊÓΣÏÕÒòËØ¡£Ê¹Óà SPSS ͳ¼ÆÈí¼þ °ü 19£¨SPSS£¬IBM£¬Chicago£¬IL£¬USA£©½øÐÐÈ«²¿Í³¼Æ·ÖÎö¡£Í³¼ÆÑ§ÒâÒåµÄÏÔÖøÐÔ¶¨ÒåΪ p <0.05¡£
ͼ 1 Öù״ͼÏÔʾµÈЧÇò¾µ¶ÈµÄ·Ö²¼
ɢͫ¼ìÓ°µÈЧÇò¾µ£¨Çü¹â¶È£©
¡¾½á¹û¡¿
×ܹ²É¸²éÁË 168 Ãû¶ùͯ¡£ÆäÖÐÓÐ 13 Ãû£¨8.4£¥£©µÄ¶ùͯ²»ÄܽøÐвâÁ¿¡£ÔÚÕâ 13 Ãû¶ùͯÖУ¬ÓÐ 5 ÈËÒò Ϊ¿Ö¾å¶ø²»ºÏ×÷£¬3 ÈËÓи߶ÈÔ¶ÊÓ°éÓÐÄÚбÊÓ£¬2 ÈËÓÐÏÈÌìÐÔÉÏíúÏ´¹£¬2 ÈËÓÐÏÈÌìÐÔÑÛÇòÕð²ü£¬1 ÈËÓÐÏÈÌìÐÔ°×ÄÚÕÏ¡£ÓÐ 155 Ãû¶ùͯ£¨310 Ö»ÑÛ£©³É¹¦µÄÍê³ÉÁ˼ì²é£¬ÄêÁ䷶ΧΪ 4-7 Ë꣨ƽ¾ù 5.74±1.20 Ë꣩¡£ÆäÖУ¬Å®º¢ÓÐ 71 ÈË£¨45.8£¥£©£¬Äк¢ÓÐ 84 ÈË£¨54.2£¥£©¡£ÓÐ 26 Ãû¶ùͯ£¨16.8£¥£©·ûºÏ PPP µÄÖ¸Ä϶¨ÒåΪÈõÊÓ 2 ¡£ÓÐ 115 Ãû£¨74.2£¥£©¶ùͯ¸ù¾ÝɢͫÑé¹âµÄ¼ì²é½á¹û£¬°´ÕÕ 2013 Äê AAPOS ±ê×¼ È·¶¨Îª¾ßÓÐÈõÊÓΣÏÕÒòËØ¡£ÆäÖУ¬65 Ãû¶ùͯ»¼ÓÐÔ¶ÊÓ£¬28 Ãû¶ùͯ»¼ÓнüÊÓ£¬59 Ãû¶ùͯ»¼ÓÐÉ¢¹â£¬32 Ãû¶ùͯ»¼ÓÐÇü¹â²Î²î£¬37 Ãû»¼ÓÐбÊÓ¡£µÈЧÇò¾µ¶ÈµÄ·Ö²¼Èçͼ 1 Ëùʾ¡£
ʹÓà Spot ÊÓÁ¦É¸²éºÍɢͫÑé¹â²âÁ¿µÄÇü¹â²»Õýƽ¾ùÖµ×ܽáÔÚ±í 1 ÖС£ÕâÁ½ÖÖ·½·¨Ëù»ñµÃµÄ½á¹ûÖ®¼ä£¬ SE ºÍÖù¾µ¶È£¨J0 ºÍ J45£©µÄ²îÒì¾ßÓÐͳ¼ÆÑ§ÒâÒ壨P <0.01£¬Wilcoxon ·ûºÅÖȼìÑ飩¡£
ʹÓà Spot ÊÓÁ¦É¸²éºÍɢͫÑé¹â²âÁ¿µÄÇü¹â²»Õýƽ¾ù²îÒì×ܽáÔÚ±í 2 ÖС£Æä²îÒ죨SSE-CRSE£©¶ÔÓ¦µÄ ƽ¾ùÖµ [£¨CRSE + SSE£©/2] ÏÔʾÔÚͼ 2 ÖС£ÔÚ 76.3£¥µÄÊÜÊÔÕßÖУ¬²îÒ죨SSE-CRSE£©ÔÚ ±1.0D ÒÔÄÚ¡£ ͬʱ£¬ÔÚ 92.7£¥µÄÊÜÊÔÕßÖÐ J0 µÄ²îÒ죬ÓëÔÚ 93.4£¥µÄÊÜÊÔÕßÖÐ J45 µÄ²îÒì¶¼ÔÚ ±1.0D ÒÔÄÚ£¨Í¼ 2B ºÍ 2C£©¡£
±í 1 Spot ºÍɢͫÑé¹âËù»ñµÃµÄƽ¾ùµÈЧÇò¾µ¶È£¨SE£©Óë Jackson ½»²æÖù¾µ¶È
| SE£¨D£© | J0£¨D£© | J45(D) |
Spot | 0.70±1.99 | 0.87±1.01 | 0.09±0.60 |
ɢͫÑé¹â | 1.19±2.22 | 0.77±1.00 | -0.02±0.45 |
| P<0.01 | P<0.01 | P<0.01 |
±í 2 Spot ºÍɢͫÑé¹âËù»ñµÃµÄƽ¾ùµÈЧÇò¾µ¶È£¨SE£©Óë Jackson ½»²æÖù¾µ¶ÈµÄ²îÒì
| SE£¨D£© | J0£¨D£© | J45(D) |
ƽ¾ùÊý ± ±ê×¼²î | -0.49±0.78 | 0.10±0.65 | 0.11±0.47 |
95%LOA | -2.96 µ½ +1.06 | -1.20 µ½ +1.40 | -0.83 µ½ +1.05 |
ÀûÓûعé·ÖÎöÀ´ÆÀ¹À Spot ºÍɢͫÑé¹âµÄ¼ì²é½á¹ûÖ®¼äµÄ¶¨Á¿¹ØÏµ¡£¶ÔÓÚµÈЧÇò¾µ¶È£¬ÏßÐԻعéÄ£ÐÍ
£¨SEspot = -0.30 + 0.84×SEcr£¬R2 = 0.88£¬P <0.01£¬Í¼ 3 ÖеĺÚÏߣ©²É¼¯µ½´ó¶àÊýµÄ±ä»¯£¬²¢ ÇÒÏÔʾ³öÇ¿ÁÒµÄÏßÐÔÏà¹Ø¡£¶þ´Î·½ºÍÈý´Î·½Ä£ÐͲ¢Ã»ÓиüºÃµÄÔö¼Ó±ä»¯µÄ½âÊÍ£¬¶þ´Î·½ºÍÈý´Î·½Ä£ Ð͵ÄÄâºÏ£¨Í¼ 3 ÖеĺìÏߺÍÀ¶Ïߣ©µÄ R2 = 0.80¡£
¶ÔÓÚ J0£¬É¢Í«Ñé¹âºÍ Spot ÊÓÁ¦É¸²éÖ®¼äµÄÏßÐÔÏà¹ØÐÔ²¢²»Ç¿ÁÒ£¨SEspot = 0.26 + 0.80×SEcr£¬R2
= 0.63£¬P <0.01£©¡£¶þ´Î·½ºÍÈý´Î·½µÄÄâºÏ²¢Ã»ÓÐÌá¸ß R2£¨¶þ´Î·½ºÍÈý´Î·½ÄâºÏµÄ R2 = 0.64£©¡£ ¶ÔÓÚ J45£¬É¢Í«Ñé¹âºÍ Spot ÊÓÁ¦É¸²éÖ®¼äµÄÏà¹ØÐÔ½øÒ»²½¼õÉÙ£¨ÏßÐÔÄâºÏµÄ R2 = 0.24£¬¶þ´Î·½ºÍ Èý´Î·½ÄâºÏ R2 = 0.64£©¡£Õâ¿ÉÄÜÊÇÓÉÓÚ´ó¶àÊýµÄÊÜÊÔÕß¾ßÓеͶÈÉ¢¹âµÄÔÒò¡£
¸ù¾Ý AAPOS ±ê×¼£¬Spot ˫ĿÊÓÁ¦É¸²éÒǼì²éÈõÊÓΣÏÕÒòËØµÄÃô¸Ð¶ÈºÍÌØÒì¶È¼û±í 3¡£
ʹÓà ROC ÇúÏßÀ´È·¶¨ Spot ÊÓÁ¦É¸²éÒǼì²éÈõÊÓΣÏÕÒòËØµÄÓÐЧÐÔ£¨Í¼ 4£©¡£Ãô¸Ð¶ÈºÍÌØÒì¶ÈµÄ*¼Ñ ½ØÖ¹µãÈç±í 4 Ëùʾ¡£×ÜÌå¶øÑÔ£¬ÓÐ 115 Àý£¨74.2£¥£©ÊÜÊÔÕß¾ßÓÐÈõÊÓΣÏÕÒòËØ£¬Spot ˫ĿÊÓÁ¦É¸²é ÒǼì²éÈõÊÓΣÏÕÒòËØµÄÃô¸Ð¶ÈΪ 94.79£¥£¬ÌØÒì¶ÈΪ 85£¥¡£
¡¾ÌÖÂÛ¡¿
ÔÚ±¾Ñо¿ÖУ¬ÎÒÃǽ« Spot ˫ĿÊÓÁ¦É¸²éÒǼì²éµÄÇü¹â²»Õý¹À¼ÆÖµÓë½ð±ê×¼——ɢͫÑé¹â¼ì²é½øÐбÈ
½Ï£¬²¢ÇÒÆÀ¹ÀÁËÆäÔÚ¼ì²éÈõÊÓΣÏÕÒòËØÖеÄÃô¸Ð¶ÈºÍÌØÒì¶È¡£ÔÚÎÒÃǵÄÑо¿ÖÐÕÐļÁË 155 ÃûÄêÁäÔÚ 4 ÖÁ 7 ËêÖ®¼äµÄ¶ùͯÑۿƾÍÕﻼÕß¡£Bland-Altman ·ÖÎöÏÔʾ£¬Spot ÊÓÁ¦É¸²éºÍɢͫÑé¹â¼ì²éÖ®¼äÓÐÖÐ µÈÒ»ÖÂÐÔ£¬ÓÈÆäÊÇ J0 ºÍ J45¡£¸ù¾Ý AAPOS 2013 Ö¸Äϵıê×¼£¬Spot ÊÓÁ¦É¸²éÏÔʾ³ö¼ì²éÈõÊÓΣÏÕÒò ËØµÄ¸ßÃô¸Ð¶ÈºÍÌØÒì¶È¡£Í¨¹ýÓÅ»¯»ùÓÚ ROC ·ÖÎöµÄÍÆ¼ö±ê×¼£¬¿ÉÒÔ½øÒ»²½Ìá¹û¡£
ͼ 2 Bland-Altmand µãͼÏÔʾ Spot ÊÓÁ¦É¸²éÓëɢͫÑé¹â£¨CR£©Ö®¼äµÄ SE¡¢J0 ºÍ J45 ÊýÖµµÄÒ»ÖÂÐÔ
Á½´Î²âÁ¿Æ½¾ùÖµ£¨Çü¹â¶È£©Á½´Î²âÁ¿Æ½¾ùÖµ£¨Çü¹â¶È£©Á½´Î²âÁ¿Æ½¾ùÖµ£¨Çü¹â¶È£©
ͼ 3 ɢͫÑé¹âºÍ Spot ˫ĿÊÓÁ¦É¸²é²âÁ¿µÄ SE Ö®¼äµÄÏà¹Ø¹ØÏµ
ɢͫµÈЧÇò¾µ£¨Çü¹â¶È£©
Spot ˫ĿÊÓÁ¦É¸²éºÍɢͫÑé¹â¼ì²éÖ®¼äµÄ±È½Ï
ÔÚÎÒÃǵÄÑо¿ÖУ¬Í¨¹ýÏßÐԻعéÄ£ÐͺܺõØ×ܽáÁË´Ó Spot ÊÓÁ¦É¸²éºÍɢͫÑé¹â¼ì²éÖлñµÃµÄ SE¡£R2
=0.88£¬ÒâζןÃÄ£ÐÍ¿ÉÒÔ½âÊÍ 88£¥µÄ±ä»¯¡£Ê¹Óöþ´Î·½»òÕßÈý´Î·½Ä£ÐÍÄâºÏÊý¾Ý²¢Ã»ÓиÄÉÆ R2¡£ ¸ù¾ÝÒÔǰµÄ Plusoptix Ñо¿£¬ÊÓÁ¦É¸²éÒǺÍɢͫÑé¹â¼ì²éÖ®¼äµÄ¹ØÏµ*ÊʺÏʹÓ÷ÇÏßÐԵĶþ´Î·½»ò ÕßÈý´Î·½ÌåÄ£ÐÍ 16 ¡£¶ÔÓÚ Plusoptix A09 ¶øÑÔ£¬¼´Ê¹Ê¹ÓÃÈý´Î·½ÄâºÏ£¬R2 Ò²½öÄÜ´ïµ½ 0.73¡£
¾¡¹Ü Spot ÊÓÁ¦É¸²éºÍɢͫÑé¹â¼ì²éµÄ²âÁ¿½á¹ûÖ®¼ä´æÔÚÓÐÁ¼ºÃµÄÏßÐÔ¹ØÏµ£¬µ«½Ø¾à²¢²»ÎªÁã¡£½Ø¾à Ϊ -0.49 D£¬Òâζ×Å Spot ÊÓÁ¦É¸²éÇãÏòÓڵ͹ÀÔ¶ÊÓ²¢ÇҸ߹À½üÊÓ¡£ÕâÖÖÇ÷ÊÆÔÚÆäËûµÄÊÓÁ¦É¸²éÒÇ£¬
Èç Plusoptix ÖУ¬Ò²Óз¢ÏÖ¡£Moghaddam ºÍ Dahlmann-Noor µÄÑо¿±¨µÀÁË Plusoptix ÊÓÁ¦É¸²éÒǺÍÉ¢ Í«Ñé¹â¼ì²éÖ®¼äµÄ²îÒìΪ 0.16 D ºÍ 0.70 D17,18¡£ÎÒÃǽ«ÕâÖÖÇãÏò¹éÒòÓÚλÖõ÷½ÚµÄÔÒò£¬ÔÚ¼ì²éû ÓÐɢͫÑé¹âµÄ¶ùͯµÄʱºò£¬²¢Ã»ÓÐÑϸñµÄ¿ØÖÆÒ»Ã×Ô¶µÄ¾àÀëÀ´½øÐС£ÀýÈ磬Èç¹û¶ùͯµÄ½üÊÓ¶ÈСÓÚ -1.0
D£¬ÕýÊÓ»òÕßÔ¶ÊÓµ÷½ÚÇ¡ºÃÊʺÏÄ¿±ê£¬¶ø Spot »áÈËΪ±¨¸æ SED ֵΪ -1.0 D¡£ÔÚѧÁäǰºÍѧÁä¶ùͯÖУ¬ ¾Ý±¨µÀ£¬Ñé¹âÆÚ¼äµ÷½ÚµÄ±äÒìÊÇÏ൱´óµÄ£¬ÓÐЩ¿ÉÒԸߴï 4.0 D19¡£Óм¸¸öÒòËØ£¬Èç¶ùͯµÄ×¢ÒâÁ¦¡¢ ÉãÏñ»úÖÜΧµÄ»·¾³µÄµ÷½Ú´Ì¼¤£¬ÒÔ¼°Ô¶ÊÓ¶ùͯµÄµ÷½ÚÖͺóµÈ£¬¶¼¿ÉÄÜ»áÔì³ÉÕâÖÖ¾Þ´ó±ä»¯¡£Õâ¿ÉÄÜ ²¿·ÖµÄ½âÊÍÁ˱¾Ñо¿Öз¢ÏÖµÄ 95£¥µÄÒ»ÖÂÐÔ¿í¶ÈÏÞÖÆ¡£
±í 3 ʹÓà AAPOS ±ê×¼¼ì²éÈõÊÓΣÏÕÒòËØµÄÃô¸Ð¶ÈºÍÌØÒì¶È
AAPOS ±ê×¼ | Ô¶ÊÓ | ½üÊÓ | É¢¹â | Çü¹â²Î²î | бÊÓ |
| >3.5D | >-1.5D | >1.5D | >1.5D | >8PD |
Ãô¸Ð¶È | 79.66% | 85.51% | 84.09% | 75.86% | 85.00% |
ÌØÒì¶È | 99.43% | 79.55% | 86.92% | 95.08% | 77.50% |
ͼ 4. ÓÃÓÚ¼ì²âÈõÊÓ£¨Ô¶ÊÓ£¬½üÊÓ£¬É¢¹â£¬Çü¹â²Î²îºÍбÊÓ£©Î£ÏÕÒòËØµÄ ROC Çú
Ô¶ÊÓ½üÊÓÉ¢¹â
1- ÌØÒì¶È
1- ÌØÒì¶È
1- ÌØÒì¶È
Çü¹â²Î²îбÊÓ
1- ÌØÒì¶È
1- ÌØÒì¶È
¼ì²éÈõÊÓΣÏÕÒòËØµÄÃô¸Ð¶È¡¢ÌØÒì¶ÈºÍ±ê×¼µÄÑ¡Ôñ
¼øÓÚ Spot ÏÖÓеľÖÏÞÐÔ£¬±¾Ñо¿Ö¼ÔÚͨ¹ýÓÅ»¯²Î¿¼±ê×¼À´Ìá¸ßɸ²éµÄÓÐЧÐÔ¡£É¸²é¹ý³ÌÐèÒªÊʵ±µÄ ƽºâÃô¸Ð¶ÈºÍÌØÒì¶È¡£¸ß¶ÈÌØÒì¶È»áʹɸ²é²úÉú×ã¹»µÄÑôÐÔÔ¤²âÖµ¡£ÓÉÓÚÈËȺÖÐÈõÊÓµÄ×ÜÌ廼²¡ÂÊ ½ÏµÍ£¬Òò´Ë¸üÎªÖØÒªµÄÊÇҪʵÏָ߶ȵÄÌØÒì¶È¡£¹ý¶à¼ÙÑôÐԵıê×¼½«µ¼Ö»¼Õß¼ÒÊô²»±ØÒªµÄѹÁ¦ºÍ ½¹ÂÇ£¬²¢ÇÒ»¹»á²úÉú²»±ØÒªµÄ¶îÍâÒ½ÁÆ·ÑÓá£ÓÉÓÚ˫ĿÊÓÁ¦É¸²éÒÇÇãÏòÓڸ߹À½üÊÓ²¢Çҵ͹ÀÔ¶ÊÓ£¬ Òò´Ë²»Ó¦¸Ã¼òµ¥µØÊ¹ÓÃɢͫÑé¹â¼ì²éµÄÈõÊÓΣÏÕÒòËØµÄ±ê×¼À´¶¨Òå·ÇɢͫÑé¹â¼ì²éµÄ²Î¿¼±ê×¼¡£Îª ÁËÔÚ¼ì²éÈõÊÓΣÏÕÒòËØ·½Ãæ´ïµ½µÄÕûÌåÓÐЧÐÔ£¬ÐèÒª¸ù¾Ý±È½Ï·ÇɢͫÑé¹âµÄɸ²é½á¹ûÓëɢͫÑé
¹âµÄ¼ì²éÊý¾ÝÀ´ÐÞ¸ÄÌØ¶¨µÄÊÓÁ¦É¸²éÒǵıê×¼¡£ÀýÈ磬Garry µÈÈ˸ù¾ÝÔÊ¼ÖÆÔìÉ̵ıê×¼£¨v1.0.3£©£¬ ±¨¸æÁË Spot ˫ĿÊÓÁ¦É¸²éÒÇµÄ 89£¥µÄÃô¸Ð¶ÈºÍ 71£¥µÄÌØÒì¶È£¬ÔÚʹÓøüеIJο¼±ê×¼ÒÔºó£¬Ãô¸Ð ¶È´ïµ½ 85£¥£¬ÌØÒì¶È´ïµ½ 88£¥£¨v1.1.51£©10¡£Peterseim Ò²ÆÀ¹ÀÁ˸üеıê×¼£¨v2.0.16£©£¬ËûÃÇ ±¨¸æµÄÃô¸Ð¶ÈΪ 87.7£¥£¬ÌØÒì¶ÈΪ 75.9£¥ 12¡£¸üÎªÖØÒªµÄÊÇ£¬ÓÉÓÚÈË¿ÚÐÅÏ¢µÄ±ä»¯£¬Ó¦¸ÃÕë¶ÔÌØ¶¨ µÄÈËȺÀ´ÓÅ»¯±ê×¼¡£ÔÚÎÒÃǵÄÑо¿ÖУ¬¶ÔÓÚ½üÊÓΪ -2.0 D µÄÓÅ»¯±ê×¼£¬ÎÒÃÇÑо¿µÄÃô¸Ð¶ÈºÍÌØÒì¶È ·Ö±ðΪ 94.79£¥ºÍ 85£¥¡£Í¨¹ýÓÅ»¯µÄÔ¶ÊÓ±ê׼Ϊ +2.375 D£¬¶ø²»ÊÇ AAPOS ÍÆ¼öµÄ +3.5D£¬Ãô¸Ð¶È´Ó
79.66£¥Ìá¸ßµ½ 98.31£¥£¬Í¬Ê±¼«ÉٵĽµµÍÌØÒì¶È¡£¶ÔÓÚÉ¢¹âºÍÇü¹â²Î²î£¬ÓÅ»¯µÄ±ê×¼·Ö±ðΪ 1.25D ºÍ 1.125D¡£ÎÒÃǵÄÑо¿½á¹ûÖ§³ÖÕâÑùµÄ¹Ûµã£ºÓÅ»¯µÄ Spot ²Î¿¼±ê×¼¶ÔÓڳɹ¦µØ³ÉΪÈõÊÓΣÏÕÒòËØµÄ ɸѡ¹¤¾ßÖÁ¹ØÖØÒª¡£
±í 4ʹÓà ROC ÇúÏß»ñµÃµÄ Spot ½ØÖ¹ÊýÖµ¼ì²é AAPOS 2013 ¶¨ÒåµÄÈõÊÓΣÏÕÒòËØµÄÃô¸Ð¶ÈºÍÌØÒì¶È
¸Ä½ø±ê×¼ | Ô¶ÊÓ | ½üÊÓ | É¢¹â | Çü¹â²Î²î | бÊÓ |
| >2.375D | >-2.00D | >1.25D | >1.125D | >12PD |
Ãô¸Ð¶È | 98.31% | 78.50% | 90.91% | 93.10% | 77.55% |
ÌØÒì¶È | 97.14% | 88.64% | 80.37% | 85.25% | 88.18% |
Spot ˫ĿÊÓÁ¦É¸²éÒǼì²éÈõÊÓΣÏÕÒòËØµÄ±È½Ï
Spot ˫ĿÊÓÁ¦É¸²éÒÇÖ÷ÒªÓÃÓÚ¼ì²éÈõÊÓΣÏÕÒòËØ¡£ÔÚÎÒÃǵÄÑо¿ÖУ¬Spot ¶ÔÈõÊÓΣÏÕÒòËØµÄ¼ì²é ¾ßÓÐ 94.79£¥µÄÃô¸Ð¶ÈºÍ 85£¥µÄÌØÒì¶È¡£Armitage Ñо¿ÁË Plusoptix S12 ÔÚ¼ì²éÈõÊÓΣÏÕÒòËØ·½Ãæ µÄÐÔÄÜ£¬Ãô¸Ð¶ÈºÍÌØÒì¶È·Ö±ðΪ 91£¥ºÍ 78£¥ 20¡£Matta µÈÈ˱¨¸æ£¬¶ÔÓÚ Plusoptix S04£¬Ãô¸Ð¶ÈΪ
99£¥£¬ÌØÒì¶ÈΪ 82£¥ 21¡£½üÀ´£¬Yan µÈÑо¿ÁË Plusoptix A09 ÔÚÑۿƾÍÕïµÄÖйú¶ùͯÈõÊÓΣÏÕÒòËØ¼ì ²éÖеÄÐÔÄÜ£¬Ãô¸Ð¶ÈºÍÌØÒì¶È·Ö±ðΪ 84.7£¥ºÍ 63.2£¥ 16¡£Spot ˫ĿÊÓÁ¦É¸²éÒÇÔÚ¼ì²éÈõÊÓΣÏÕÒòËØ ·½ÃæµÄÐÔÄÜ£¬ËƺõÓÅÓÚ Plusoptix S12 ºÍ Plusoptix A09£¬²¢ÓÚ Plusopix S04 ³Öƽ¡£
Spot ˫ĿÁ¦É¸²éÒǼì²éбÊÓ
ÓÉÓÚ APOS 2013 Ö¸ÄÏÖв»°üÀ¨¼äЪÐÔÍâбÊÓ£¬Òò´ËÔÚ±¾Ñо¿Öнö½ö¿¼ÂÇÁËÃ÷ÏÔµÄбÊÓ 13¡£ÔÚÓÅ»¯±ê ×¼ÒÔºó£¬Ã÷ÏÔбÊÓ¼ì²éµÄÃô¸Ð¶ÈºÍÌØÒì¶È·Ö±ðΪ 77.55£¥ºÍ 88.18£¥¡£ÔÚ Spot ²âÁ¿ÆÚ¼ä£¬ÎÒÃÇ×¢Òâ µ½ÑÛ¾¦Æ«²îµÄ½á¹û¿ÉÄÜ»áÊܵ½Í·²¿×ËÊÆµÄÓ°Ïì¡£Èç¹ûÔÚÅÄÉãÕÕÆ¬Ê±£¬ÅÄÉã¶ÔÏóÅöÇÉÍ·²¿Çãб£¬ÄÇô Spot ˫ĿÊÓÁ¦É¸²éÒÇ¿ÉÄÜ»á´íÎ󵨽«Õý³£ÊÜÊÔÕß±¨¸æÎªÐ±ÊÓ¡£Òò´Ë£¬Ó¦¸Ã²ÉÈ¡´ëÊ©±£³ÖÍ·²¿×ËÊÆ£¬ ÓÈÆä¶ÔÓÚ¶ùͯ¡£±¾Ñо¿µÄÁíÍâÒ»¸öÏÞÖÆÊÇʹÓÃÈõÊÓΣÏÕÒòËØ½Ï¸ß»¼²¡ÂʵÄÁÙ´²»¼Õߣ¬¶ø²»ÊÇ»ùÓÚÉçÇø¡¢ È˿ڻòÕßѧУµÄ¶ùͯÑù±¾¡£
¡¾½áÂÛ¡¿
Spot ˫ĿÊÓÁ¦É¸²éÒDzâÁ¿µÄÇü¹âÖµÏÔʾ³öÓëɢͫÑé¹â¼ì²é½á¹ûµÄÖеÈÒ»ÖÂÐÔ¡£Spot ˫ĿÊÓÁ¦É¸²éÒÇ ÔÚ¼ì²é¸öÌåÈõÊÓΣÏÕÒòËØ·½ÃæµÄ±íÏÖÁîÈËÂúÒ⣬²¢ÇÒ¿ÉÒÔͨ¹ý»ùÓÚ ROC ÇúÏßµÄÓÅ»¯±ê×¼½øÒ»²½¸Ä½ø¡£ ÕâЩ·¢ÏÖ±íÃ÷£¬Spot ˫ĿÊÓÁ¦É¸²éÒÇ¿ÉÄÜÊÇÔÚÖйúÈË¿ÚÖнøÐдó¹æÄ£ÈËȺɸ²éµÄ·Ç³£ÓÐÓõŤ¾ß¡£
¡¾²Î¿¼ÎÄÏס¿
1. Simons K. Amblyopia characterization, treatment, and prophylaxis. Surv Ophthalmol. 2005; 50(2):123–66. PMID: 15749306.
2. American Academy of Ophthalmology Pediatric Ophthalmology/Strabismus Panel. Preferred Practice Pattern Guidelines. Amblyopia. San Franciso, CA: American Academy of Ophthalmology; 2012. Available:
3. Lagreze WA. Vision screening in preschool children: do the data support universal screening? Dtsch
Arztebl Int. 2010; 107(28–29):495–9. doi: 10.3238/arztebl.2010.0495 PMID: 20703333.
4. Vision screening for children 1 to 5 years of age: US Preventive Services Task Force Recommendation statement. Pediatrics. 2011; 127(2):340–6. doi: 10.1542/peds.2010-3177 PMID: 21282267.
5. Pediatric Eye Disease Investigator G. The course of moderate amblyopia treated with atropine in children:
experience of the amblyopia treatment study. Am J Ophthalmol. 2003; 136: 630–639. PMID: 14516802.
6. American Academy of Pediatrics, Section on Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Academy of Ophthalmology; American Association of Certified Orthoptists. Red reflex examination in neonates, infants, and children. Pediatrics 2008; 122:1401–1404. doi: 10.1542/peds.2008-2624 PMID: 19047263.
7. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (eds.):Früherkennungsuntersuchung von Sehstörungen bei Kindern bis zur Vollendung des 6. Lebensjahres.
8. Carlton J, Karnon J, Czoski-Murray C, Smith KJ, Marr J: The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4–5 years: a systematic review and economic evaluation. Health Technol Assess 2008; 12: iii, xi-194.
9. Donahue SP, Ruben JB, American Academy of O, American Academy of Pediatrics OS, American Association for Pediatric O, Strabismus, et al. US Preventive Services Task Force vision screening recommendations. Pediatrics. 2011; 127(3):569–70. doi: 10.1542/peds.2011-0020 PMID: 21282266.
10. Garry GA, Donahue SP. Validation of Spot screening device for amblyopia risk factors. J aapos. 2014;
18(5):476–80. doi: 10.1016/j.jaapos.2014.07.156 PMID: 25266832.
11. Silbert DI, Matta NS. Performance of the Spot vision screener for the detection of amblyopia risk factors in children. J AAPOS. 2014; 18(2):169–72. doi: 10.1016/j.jaapos.2013.11.019 PMID: 24698615.
12. Peterseim MM, Papa CE, Wilson ME, Davidson JD, Shtessel M, Husain M, et al. The effectiveness of the Spot Vision Screener in detecting amblyopia risk factors. J AAPOS. 2014; 18(6):539–42. doi: 10. 1016/ j.jaapos.2014.07.176 PMID: 25498463.
13. Donahue SP, Arthur B, Neely DE, Arnold RW, Silbert D, Ruben JB. Guidelines for automated preschool vision screening: a 10-year, evidence-based update. J aapos. 2013; 17(1):4–8. doi: 10.1016/j.jaapos.
2012.09.012 PMID: 23360915.
14. Chen X, Fu Z, Yu J, Ding H, Bai J, Chen J, et al. Prevalence of amblyopia and strabismus in Eastern China: results from screening of preschool children aged 36–72 months. The British journal of ophthalmology. 2015.
15. Welch Allyn1Spot1Vision Screener Model VS100 2016. Available:
dam/welchallyn/documents/sap-documents/LIT/80020/80020275LITPDF.pdf.
16. Yan XR, Jiao WZ, Li ZW, Xu WW, Li FJ, Wang LH. Performance of the Plusoptix A09 photoscreener in detecting amblyopia risk factors in Chinese children attending an eye clinic. PLoS One. 2015; 10(6): e0126052. doi: 10.1371/journal.pone.0126052 PMID: 26030210.
17. Dahlmann-Noor AH, Vivian AJ. A comparison of photorefraction and retinoscopy in children. J aapos.
2008; 12(1):104; author reply -5. PMID: 18155941.
18. Moghaddam AA, Kargozar A, Zarei-Ghanavati M, Najjaran M, Nozari V, Shakeri MT. Screening for amblyopia risk factors in pre-verbal children using the Plusoptix photoscreener: a cross-sectional population-based study. The British journal of ophthalmology. 2012; 96(1):83–6. doi: 10.1136/bjo.2010.
190405 PMID: 21515564.
19. Schimitzek T, Lagreze WA. Accuracy of a new photo-refractometer in young and adult patients. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2005; 243(7):637–45.
20. Kirk S, Armitage MD, Dunn S, Arnold RW. Calibration and validation of the 2WIN photoscreener compared to the PlusoptiX S12 and the SPOT. J Pediatr Ophthalmol Strabismus. 2014; 51(5):289–92. doi: 10.3928/01913913-20140701-01 PMID: 25000209.